Liability · Defenses · 2026-05-24
Defenses and what to do today
What will a treating physician or clinic argue in a disciplinary complaint or civil case? The defenses are predictable — and not always strong.
"We followed the Dutch guideline"
A guideline is not a safe harbor. Medical protocols ordinarily help to fill in the professional standard, but according to Smeehuijzen, Smids and Hoekstra a protocol can only do so if it is evidence-based, carries a limited medical-ethical charge and came about through an adequate process; they argue that the Dutch guideline does not meet these conditions and that a civil court should not treat it as a yardstick.1 Moreover, a physician relying exclusively on a guideline that is questioned abroad (the UK, Finland and Sweden are reforming their approach) and in the Netherlands (for example by medical ethicist Jilles Smids in the Nederlands Tijdschrift voor Geneeskunde, source) may be told that a reasonably competent colleague would not ignore that signal.
"The patient and parents signed"
Consent is valid only when based on full and honest information (art. 7:448 and 7:450 BW). A signature on a form is not proof of valid consent if the underlying information fell short. See informed consent as the strongest route.
"WPATH SOC-8 is the international standard"
The WPATH guideline came under fire in 2024. The BMJ reported that Johns Hopkins researchers who carried out evidence reviews for WPATH wrote of "issues with this sponsor trying to restrict our ability to publish" (WPATH denied that it prohibited publication), and that documents show pressure from high within the US government to remove minimum age recommendations, which WPATH removed after the American Academy of Pediatrics threatened to denounce the guidelines (source). Environmental Progress published the so-called WPATH Files, from which it concludes that WPATH does not meet the standards of evidence-based medicine; that is Environmental Progress's reading, and of the members contacted, one confirmed their own statements and another disputed the interpretation (source).2 Critics argue that this has damaged the status of SOC-8 as an independent scientific standard. Reliance on WPATH does not exempt a Dutch physician from independent critical review.
"Not treating is also harmful — suicide risk"
This argument is deployed often and is emotionally powerful: without treatment the patient would become suicidal. The Cass Review notes that it has been suggested that hormone treatment reduces the elevated risk of death by suicide in this population, but that the evidence found did not support this conclusion (source; see also Biggs3). The Dutch Health Council (2026), for its part, sees indications of some improvement in mental outcomes after treatment (certainty of evidence low to very low) and weighs that doing nothing can also harm mental health (source). The argument therefore does not by itself displace a duty of disclosure or duty of care.
"The state of science justified it at the time"
Here time becomes decisive. The ex tunc criterion (judgment by what was known at the time) is a valid legal principle. But the relevant question becomes: from when on should the physician have known better? For treatments in 2018 the answer differs from treatments in 2024. From the NICE evidence reviews of October 2020 the appeal to ignorance has weakened. From the Cass Review (April 2024) it is barely sustainable.
The international precedents are already in place
In the United Kingdom, Keira Bell — a woman who as a minor received puberty blockers, then testosterone, and ultimately a mastectomy, and who later detransitioned — brought proceedings against the Tavistock clinic. She prevailed at first instance (December 2020); on 17 September 2021 the Court of Appeal allowed the Trust's appeal (judgment summary). In March 2024 NHS England ended the routine commissioning of puberty blockers for under-18s (source); the Cass Review, which NHS England had commissioned in 2020, published its final report in April 2024.4
In the United States, former patients who later detransitioned have brought civil lawsuits against clinicians; Chloe Cole, for example, sued Kaiser Permanente and three treating professionals in California in February 2023 (source).
In the Netherlands this terrain is legally untrodden. But the legal toolbox — Wgbo, BIG Act, Book 6 of the Civil Code, UN Convention on the Rights of the Child — is ready. The question is not whether the first cases will come, but when.
What a physician must do today
This dossier is not an indictment of physicians who in good faith, within prior understanding, delivered this care. It is a warning about what is done from today onward. For the physician who in 2026 has patient contact about these treatments, the following applies:
- Actively engage with the Cass Review, the Swedish SBU review, the Finnish COHERE guideline and the Dutch Health Council advice of June 2026. Ignorance is no longer a defense.
- Document in the record exactly what information was provided on uncertainty of effectiveness, irreversibility, fertility loss and alternatives. A signature without an underlying conversation record offers no protection.
- Ensure that comorbidity (autism, depression, trauma, eating disorders) has been explored and, where indicated, treated before hormonal intervention is considered. This is not a checkbox but an independent duty of care.
- Discuss desistance and the fact that in Dutch and UK cohort studies 93–98% of adolescents on puberty blockers proceeded to cross-sex hormones (source). The pause-button metaphor therefore needs qualification; the authors of the Brik study note that the high progression rate may reflect eligibility criteria that select those highly likely to continue (source).
- Be restrained with minors. Competence for lifelong, far-reaching decisions is contested.
- Do not rely exclusively on the Dutch guideline or WPATH SOC-8. Both are contested. Individual professional judgment governs.
- Bear in mind that records are requested long after treatment: limitation periods for damages claims (art. 3:310 BW) run from the moment the claimant learns of the damage and of the liable party, so claims can come years after the treatment.
Conclusion
Rarely has an entire branch of medical treatment come under such fundamental international fire within five years. Rarer still is that the clinicians themselves, in their own scientific publications, want to set aside the traditional medico-scientific framework for that treatment.
That is not background noise. That is a shifted legal reality. The Wgbo does not change, disciplinary law does not change, Book 6 of the Civil Code does not change. But what counts as the good-clinician standard, what counts as full disclosure, and what a reasonably competent colleague is taken to know — that shifts. Quickly.
The medical maxim primum non nocere says it — above all, do no harm. It is an obligation that does not require statistical certainty to engage. Doubt suffices. And the doubt is there, voiced not by outside critics but by the clinicians themselves. Those who proceed today as though nothing is the matter will operate not only in the consulting room. But also in the courtroom.
Notes
- Smeehuijzen JL, Smids J, Hoekstra C. Transgenderzorg aan kinderen. Juridische bedenkingen bij het Dutch Protocol (2018). NJB 2023/1772, issue 25, 14 July 2023 (njb.nl).
- Hughes M. The WPATH Files: Pseudoscientific surgical and hormonal experiments on children, adolescents, and vulnerable adults. Environmental Progress, March 2024.
- Biggs M. Suicide by clinic-referred transgender adolescents in the United Kingdom. Archives of Sexual Behavior. 2022;51:685–690.
- Bell v Tavistock [2020] EWHC 3274 (Admin); [2021] EWCA Civ 1363.